Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide

This 2022 study evaluates the repurposing of clindamycin (CLD), a macrolide antibiotic, as a novel therapeutic agent for drug-resistant glioblastoma (GBM). CLD was shown to inhibit tumor cell growth by targeting the mTORC1 signaling pathway, reducing phosphorylation of downstream targets p70S6K and S6. Importantly, CLD also suppressed MGMT expression, a